Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Nippon Shinyaku CoTSE:4516 +0.80%80 3-Year EBITDA Growth Rate is 6.60% as of Jun. 2026, which is 15% below its 10-year median of 7.80. GuruFocus rates TSE:4516 with a GF Score™ of 80/100 and a GF Value™ of 円4,650.06 (Modestly Undervalued). The stock has 2 warning signs investors should review. Among 805 Drug Manufacturers companies, Nippon Shinyaku Co ranks worse than 53.91% on this metric.
During the past 12 months, Nippon Shinyaku Co's average EBITDA Per Share Growth Rate was 10.50% per year.
During the past 3 years, the average EBITDA Per Share Growth Rate was 6.60% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was 5.60% per year.
During the past 10 years, the average EBITDA Per Share Growth Rate was 12.70% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of Nippon Shinyaku Co was 29.80% per year. The lowest was -8.10% per year. And the median was 7.80% per year.
Nippon Shinyaku Co (TSE:4516) 3-Year EBITDA Growth Rate Explanation
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Nippon Shinyaku Co 3-Year EBITDA Growth Rate Related Terms
TSE:4516 vs ZTS: 3-Year EBITDA Growth Rate Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Nippon Shinyaku Co's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Nippon Shinyaku Co 3-Year EBITDA Growth Rate vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Nippon Shinyaku Co's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Nippon Shinyaku Co's 3-Year EBITDA Growth Rate falls into.
Nippon Shinyaku Co 3-Year EBITDA Growth Rate Calculation
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 6.60% mean?
Nippon Shinyaku Co (TSE:4516) has a 3-Year EBITDA Growth Rate of 6.60% as of Jun. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Nippon Shinyaku Co and its competitors. This is 15% below median its historical median of 7.80. According to the industry distribution chart, Nippon Shinyaku Co ranks #434 out of 805 companies in the Drug Manufacturers industry, placing it in the top 53.9%.
Is Nippon Shinyaku Co's 3-Year EBITDA Growth Rate too high?
Nippon Shinyaku Co's current 3-Year EBITDA Growth Rate of 6.60% is 15% below median its 10-year median of 7.80. The Drug Manufacturers industry median 3-Year EBITDA Growth Rate is 8.90. Nippon Shinyaku Co's value of 6.60% is 25.8% below this industry median. Based on the distribution chart, Nippon Shinyaku Co ranks #434 out of 805 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Nippon Shinyaku Co has a GF Score™ of 80/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Nippon Shinyaku Co's 3-Year EBITDA Growth Rate compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Nippon Shinyaku Co ranks #434 out of 805 companies for 3-Year EBITDA Growth Rate. This places Nippon Shinyaku Co in the lower half of its industry. The industry median 3-Year EBITDA Growth Rate is 8.90. Nippon Shinyaku Co's value of 6.60% is 25.8% below this benchmark. While the company's 10-year median is 7.80 vs. the industry median of 8.90, Nippon Shinyaku Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Drug Manufacturers company?
The median 3-Year EBITDA Growth Rate among Drug Manufacturers companies is 8.90, based on 805 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Nippon Shinyaku Co's current 3-Year EBITDA Growth Rate of 6.60% is 25.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Nippon Shinyaku Co and its competitors. For the Drug Manufacturers industry, the median 3-Year EBITDA Growth Rate is 8.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Nippon Shinyaku Co's current 3-Year EBITDA Growth Rate is 6.60%, which is 15% below median its own 10-year median of 7.80. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nippon Shinyaku Co stock overvalued right now?
Based on GuruFocus' analysis, Nippon Shinyaku Co (TSE:4516) is currently considered Modestly Undervalued. The stock's GF Value™ is 円4,650.06, compared to a current price of 円3,386.00 — trading 27.2% below its estimated fair value. The current 3-Year EBITDA Growth Rate is 6.60%, which is 15% below median its 10-year median of 7.80 and 25.8% below the Drug Manufacturers industry median of 8.90. Nippon Shinyaku Co's overall GF Score™ is 80/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Nippon Shinyaku Co (TSE:4516), the current 3-Year EBITDA Growth Rate is 6.60% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Nippon Shinyaku Co (TSE:4516) Overvalued in 2026?
Based on GuruFocus' analysis, Nippon Shinyaku Co stock appears to be undervalued.
The current stock price of 円3,386.00 is trading 27.2% below its estimated GF Value™ of 円4,650.06.
GuruFocus considers Nippon Shinyaku Co to be Modestly Undervalued.
Key valuation signals for TSE:4516:
3-Year EBITDA Growth Rate: 6.60% (15% below median its 10-year median of 7.80)
GF Value™: 円4,650.06 vs. price of 円3,386.00 (27.2% below fair value)
Industry Position: 25.8% below the Drug Manufacturers median (#434 of 805)
No single metric tells the full story. See the TSE:4516 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Nippon Shinyaku Co Ltd is engaged in the pharmaceuticals and functional food businesses. The Pharmaceuticals Business develops and sells treatments for urological disorders, blood cancer, rare and intractable diseases, and gynecological conditions. The Functional Food Business produces and sells health food ingredients, quality-stabilizing preservatives, protein preparations, and supplements. It generates the majority of its revenue from the Pharmaceuticals segment.
80GF Score
Get the complete analysis for TSE:4516
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:4516 has been successfully added to your 
